Matt Newbold Bio

Matt works closely with management teams across the Midlands looking to grow their business and is responsible for identifying ambitious teams that would benefit from the support of a private equity partner. Since joining LDC in 2012, Matt has invested more than £300million across a number of high-profile businesses in the UK, including Deltron, IWS Group, Kingswood ,The NEC Group, BioZone Scientific, Prism Medical, Stuart Turner, Eley, SMH Fleet, Centiq, Ross Trustees, Eley, and CitySprint, averaging over 3x return on realised investments. Matt is currently Investor Director on the Boards of Kingswood Healthcare and Cardel and also sits on the UK & European Capital Committee for the BVCA which represents the interests of the BVCA’s mid-market members. Previous Board positions include Stuart Turner, Kee Safety, Prism Medical, and CitySprint. Matt recently spoke with private equity news title Real Deals about LDC’s track record in the healthcare sector – read more here. After graduating from Nottingham Trent University with a First Class Degree in Accounting & Finance and qualifying as a Chartered Accountant, Matt gained eight years of corporate finance experience with PwC and Alantra, working in the UK and North America.